Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Synergism Or Long Duration (SOLD) Study (SOLD)

This study has been completed.
Information provided by (Responsible Party):
Finnish Breast Cancer Group Identifier:
First received: January 3, 2008
Last updated: March 5, 2015
Last verified: March 2015
The purpose of the study is to compare disease-free survival (DFS) of women treated with concomitant trastuzumab plus docetaxel followed by FEC to that of the women treated with the same regimen followed by single-agent trastuzumab to complete one year of trastuzumab administration as adjuvant treatments of early HER2-positive breast cancer.

Condition Intervention Phase
Breast Neoplasms
Drug: trastuzumab (9 weeks) + docetaxel
Drug: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer

Resource links provided by NLM:

Further study details as provided by Finnish Breast Cancer Group:

Primary Outcome Measures:
  • Disease-free survival (DFS) [ Time Frame: 3-10years ]

Secondary Outcome Measures:
  • Overall survival, distant disease-free survival, cardiac event-free disease-free survival, left ventricle ejection fractions, adverse events, quality of life [ Time Frame: 3-10years ]

Enrollment: 2168
Study Start Date: January 2008
Study Completion Date: November 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 -> FE75C x3)
Drug: trastuzumab (9 weeks) + docetaxel

Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:

A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)

Active Comparator: B
Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
Drug: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient has provided a written informed consent prior to study-specific screening procedures, with the understanding that she has the right to withdraw from the study at any time, without prejudice.
  2. Woman > 18 years of age.
  3. Histologically confirmed invasive breast cancer.
  4. HER2-positive breast cancer (preferably assessed with CISH or FISH; if not available with immunohistochemistry 3+)
  5. A high risk of breast cancer recurrence with one of the following:

    • Pathological N0 with the longest invasive tumor diameter >5 mm
    • Histologically confirmed regional node positive disease (pN+; nodal isolated tumor cells/cell clusters < 0.2 mm in diameter (ITP) are not counted as a metastasis)

Exclusion Criteria:

  1. Presence of distant metastases.
  2. Inflammatory breast cancer.
  3. pT1bN0M0 (i.e. the longest tumor diameter 6 to 10 mm, node-negative) and histological grade 1.
  4. Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia not well controlled with medication) or myocardial infarction within the last 12 months.
  5. Left ventricular ejection fraction less than 50% (or under the institutional normal reference range) assessed by echocardiography or isotope cardiography.
  6. ER, PgR and HER-2 status (via in situ hybridization or immunohistochemistry) not determined.
  7. Primary systemic cancer therapy (neoadjuvant chemotherapy or endocrine therapy) has been administered prior to breast surgery.
  8. The WHO performance status > 1.
  9. Pregnant or lactating women.
  10. Women of childbearing potential unless using a reliable and appropriate contraceptive method. Women must have been amenorrheic for at least 12 months prior to study entry to be considered postmenopausal and to have no childbearing potential. Women of childbearing potential (menstruating within 12 months of study entry), or with no hysterectomy and age < 55, must have a negative pregnancy test at baseline.
  11. More than 12 weeks between breast surgery and date of randomization.
  12. Organ allografts with immunosuppressive therapy required.
  13. Major surgery (except breast surgery) within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery.
  14. Participation in any investigational drug study within 4 weeks preceding treatment start.
  15. Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding study participation.
  16. History of another malignancy within the last five years except cured basal cell carcinoma of skin or carcinoma in situ of the uterine cervix.
  17. One or more of the following:

    • Blood hemoglobin < 10.0 g/dL, neutrophils < 1.5 x 109/L, platelet count < 120 x 109/L
    • Serum/plasma creatinine > 1.5 x Upper Limit of Normal (ULN)
    • Serum/plasma bilirubin > ULN
    • Serum/plasma ALT and/or AST > 1.5 x ULN
    • Serum/plasma alkaline phosphatase > 2.5 x ULN
  18. Serious uncontrolled infection or other serious uncontrolled concomitant disease.
  19. Unwilling or unable to comply with the protocol for the duration of the study.
  20. History of hypersensitivity to the investigational products or to drugs with similar chemical structures.
  21. Pre-existing motor or sensory neurotoxicity of a severity ≥ grade 2 by CTCAE version 3, unless related to mechanical etiology.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00593697

Helsinki University Central Hospital, Department of Oncology
Helsinki, Finland, 00029 HUS
Sponsors and Collaborators
Finnish Breast Cancer Group
  More Information

Responsible Party: Finnish Breast Cancer Group Identifier: NCT00593697     History of Changes
Other Study ID Numbers: Protocol number FBCSG-01-2007
EudraCT number 2007-002016-26
Study First Received: January 3, 2008
Last Updated: March 5, 2015

Keywords provided by Finnish Breast Cancer Group:
breast cancer
adjuvant therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017